<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40188190</article-id><article-id pub-id-type="pmc">PMC11972316</article-id><article-id pub-id-type="publisher-id">919</article-id><article-id pub-id-type="doi">10.1038/s41531-025-00919-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Comment</subject></subj-group></article-categories><title-group><article-title>Application of new biologic disease criteria for synucleinopathies to the systemic synuclein sampling study cohort</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chahine</surname><given-names>L. M.</given-names></name><address><email>lchahine2018@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brumm</surname><given-names>M. C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nair</surname><given-names>A. R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mosovsky</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Polinski</surname><given-names>N. K.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Beach</surname><given-names>T. G.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mollenhauer</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Adler</surname><given-names>C. H.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="IAu1"><collab>On behalf of the Systemic Synuclein Sampling Study<contrib-group><contrib contrib-type="author"><name><surname>Akhtar</surname><given-names>Rizwan</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Amara</surname><given-names>Amy</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Arnedo</surname><given-names>Vanessa</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Breen</surname><given-names>David P.</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Brumm</surname><given-names>Michael C.</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Caspell-Garcia</surname><given-names>Chelsea</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Coffey</surname><given-names>Christopher</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Crary</surname><given-names>John</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Dave</surname><given-names>Kuldip</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Foroud</surname><given-names>Tatiana</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Hogarth</surname><given-names>Penelope</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Jennings</surname><given-names>Danna</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Kopil</surname><given-names>Katherine</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Linder</surname><given-names>Carly</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Marras</surname><given-names>Connie</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Munoz</surname><given-names>David</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>Luis</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Riley</surname><given-names>Lindsey</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>David</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Seibyl</surname><given-names>John</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Serrano</surname><given-names>Geidy E.</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Visanji</surname><given-names>Naomi</given-names></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Charles L.</given-names><suffix>III</suffix></name><xref rid="IAu1" ref-type="contrib"/><xref ref-type="aff" rid="Aff23">23</xref></contrib></contrib-group></collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01an3r305</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>Department of Neurology, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036jqmy94</institution-id><institution-id institution-id-type="GRID">grid.214572.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8294</institution-id><institution>Department of Biostatistics, </institution><institution>University of Iowa College of Public Health, </institution></institution-wrap>Iowa City, IA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03arq3225</institution-id><institution-id institution-id-type="GRID">grid.430781.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 5907 0388</institution-id><institution>The Michael J. Fox Foundation for Parkinson&#x02019;s Research, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gjkkf30</institution-id><institution-id institution-id-type="GRID">grid.414208.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0619 8759</institution-id><institution>Banner Sun Health Research Institute, </institution></institution-wrap>Sun City, AZ USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0270sxy44</institution-id><institution-id institution-id-type="GRID">grid.440220.0</institution-id><institution>Center of Parkinsonism and Movement Disorders, Department of Neurology, </institution><institution>Paracelsus-Elena Klinik Kassel and University Medical Center G&#x000f6;ttingen, </institution></institution-wrap>G&#x000f6;ttingen, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qp3tb03</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Department of Neurology, </institution><institution>Mayo Clinic College of Medicine, </institution></institution-wrap>Scottsdale, AZ USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/019t2rq07</institution-id><institution-id institution-id-type="GRID">grid.462972.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0466 9414</institution-id><institution>Ken and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, </institution><institution>Northwestern University Feinberg School of Medicine, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wmf1y16</institution-id><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Department of Neurology, </institution><institution>University of Colorado Anschutz Medical Campus, </institution></institution-wrap>Aurora, CO USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01nrxwf90</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution>University of Edinburgh, </institution></institution-wrap>Edinburgh, UK </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a9tmd77</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Departments of Pathology, Neuroscience, and Artificial Intelligence &#x00026; Human Health, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mwp5989</institution-id><institution-id institution-id-type="GRID">grid.430438.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0590 7963</institution-id><institution>The ALS Association, </institution></institution-wrap>Arlington, VA USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gxnyn08</institution-id><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution>Indiana University, </institution></institution-wrap>Indianapolis, IN USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/009avj582</institution-id><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution>Oregon Health and Science University, </institution></institution-wrap>Portland, OR USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pprn321</institution-id><institution-id institution-id-type="GRID">grid.491115.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 5912 9212</institution-id><institution>Denali Therapeutics Inc., </institution></institution-wrap>South San Francisco, CA USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b30xv10</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Perelman School of Medicine at the University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>The Edmond J. Safra Program in Parkinson&#x02019;s Disease, University Health Network, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, Ontario Canada </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04skqfp25</institution-id><institution-id institution-id-type="GRID">grid.415502.7</institution-id><institution>St. Michael&#x02019;s Hospital, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/022hrs427</institution-id><institution-id institution-id-type="GRID">grid.429091.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 5913 3633</institution-id><institution>Institute for Neurodegenerative Disorders, </institution></institution-wrap>New Haven, CT USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05vagpr62</institution-id><institution>Krembil Brain Institute, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qv8yq19</institution-id><institution-id institution-id-type="GRID">grid.417188.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0012 4167</institution-id><institution>Edmond J Safra Program in Parkinson Disease, Parkinson Foundation Centre of Excellence, </institution><institution>Toronto Western Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Department of Laboratory Medicine and Pathobiology, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Tanz Centre for Research in Neurodegenerative Diseases, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05byvp690</institution-id><institution-id institution-id-type="GRID">grid.267313.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9482 7121</institution-id><institution>Department of Pathology, </institution><institution>University of Texas Southwestern Medical Center, </institution></institution-wrap>Dallas, TX USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><elocation-id>69</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1" abstract-type="teaser"><p id="Par1">We applied biologic criteria and NSD-ISS to Synuclein Sampling Study, a PD sample with range of durations since clinical diagnosis. 93% of evaluable participants met biologic criteria. The majority were NSD-ISS stage3 or less, including &#x0003e;40% of the advanced PD group. Interpretation of staging in medicated patients is challenging. Biologic criteria and clinico-biomarker staging are important steps forward, but quantitative biomarkers of disease progression, not influenced by medications, are critically needed.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Neuroscience</kwd><kwd>Neurology</kwd><kwd>Neurodegenerative diseases</kwd><kwd>Parkinson's disease</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000864</institution-id><institution>Michael J. Fox Foundation for Parkinson's Research</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par2">We read with interest the article by Dam et al.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. There have been two newly proposed biologic criteria for Parkinson&#x02019;s disease (PD), partially defined by in vivo evidence of pathologic alpha-synuclein (asyn) and neurodegeneration (termed Neuronal &#x003b1;-Synuclein Disease [NSD] by Simuni et al.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> and SynNeurGe by H&#x000f6;glinger et al.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>). In addition to proposing this new biologic definition, Simuni et al. put forth a staging system, the Neuronal &#x003b1;-Synuclein Disease Integrated Staging System (NSD-ISS). In the manuscript by Dam et al., criteria are proposed to define stages 0&#x02013;6 of the NSD-ISS and they report results of applying these criteria to cohorts of individuals with a clinical diagnosis of early PD.</p><p id="Par3">We have applied the NSD, NSD-ISS, and SynNeurGe to an independent cohort, the Systemic Synuclein Sampling Study (S4)<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref></sup>. The S4 aimed to examine the distribution of abnormal alpha-synuclein across different tissues and body fluids in PD; the study sample and available data<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> offer a prime opportunity for the present post-hoc analysis. Unlike the cohorts examined by Dam et al., the S4 sample is comprised of individuals with a range of disease durations and severities, defined as follows: early PD (&#x02264;&#x02009;2 years since diagnosis, not treated with dopaminergic medication (exceptions made for rasagiline)), moderate PD (&#x0003e;2 but &#x0003c;5 years since diagnosis, treated with dopaminergic medication but without motor fluctuations), and advanced PD (&#x02265;5 years since diagnosis, with motor fluctuations). Other enrollment criteria were reduced dopamine transporter binding on SPECT scan (based on visual interpretation) and absence of dementia. Aggregated asyn was assessed in CSF and submandibular gland with asyn seed amplification assay (SAA), and in skin, submandibular gland, and colon with immunohistochemistry, as described<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par4">The study enrolled 61 individuals with a clinical diagnosis of PD (20 early, 20 moderate, 21 advanced). CSF was not available from seven (four early, two moderate, one advanced), and four were CSF asyn SAA negative (two moderate, two advanced). None of the participants had known pathogenic variants in LRRK2, GBA, or other PD-associated genes<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Thus, 50 individuals with a clinical diagnosis of PD (82% of those enrolled and 93% of those from whom CSF was available) met criteria for NSD (S&#x02009;+&#x02009;D&#x02009;+&#x02009;G&#x02212;) and SynNeurGe (Syn+Neur+Ge&#x02212;).</p><p id="Par5">Despite differences in enrollment criteria, the majority of the sample, 33/50 (66%), were NSD-ISS stage 3, similar to the Dam et al. study (Table <xref rid="Tab1" ref-type="table">1</xref>). Half of the advanced PD group were stage 4, but two (13%) of the early PD group were stage 4 as well, consistent with findings by Dam et al. that a recent diagnosis is not a sufficient indicator of early/mild disease severity.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics and NSD-ISS stages of S4 study participants who met NSD and SynNeurGe criteria, according to enrollment cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All PD<break/>(<italic>N</italic>&#x02009;=&#x02009;50)</th><th>Early PD<break/>(<italic>N</italic>&#x02009;=&#x02009;16)</th><th>Moderate PD<break/>(<italic>N</italic>&#x02009;=&#x02009;16)</th><th>Advanced PD<break/>(<italic>N</italic>&#x02009;=&#x02009;18)</th><th>p-value</th></tr></thead><tbody><tr><td>Age, mean (SD) years</td><td>63.1 (8.4)</td><td>62.0 (9.7)</td><td>59.4 (5.3)</td><td>67.4 (7.8)</td><td>0.0054</td></tr><tr><td>Time since diagnosis, mean (SD) years</td><td>4.8 (4.6)</td><td>0.8 (0.7)</td><td>3.6 (1.2)</td><td>9.4 (4.4)</td><td>&#x0003c;0.0001<sup>a</sup></td></tr><tr><td>LEDD, mean (SD) mg</td><td>460.0 (443.0)</td><td>37.5 (61.9)</td><td>405.3 (182.9)</td><td>884.2 (414.2)</td><td>&#x0003c;0.0001</td></tr><tr><td>NSD-ISS Stage</td><td/><td/><td/><td/><td>0.0056<sup>b</sup></td></tr><tr><td>&#x02003;Stage 2B, N (%)</td><td>4 (8%)</td><td>2 (13%)</td><td>1 (6%)</td><td>1 (6%)</td><td/></tr><tr><td>&#x02003;Stage 3, N (%)</td><td>33 (66%)</td><td>12 (75%)</td><td>14 (88%)</td><td>7 (39%)</td><td/></tr><tr><td>&#x02003;Stage 4, N (%)</td><td>12 (24%)</td><td>2 (13%)</td><td>1 (6%)</td><td>9 (50%)</td><td/></tr><tr><td>&#x02003;Stage 5, N (%)</td><td>1 (2%)</td><td>0</td><td>0</td><td>1 (6%)</td><td/></tr></tbody></table><table-wrap-foot><p><italic>LEDD</italic> Levodopa equivalent dosage.</p><p><sup>a</sup>PD groups were recruited based on time since diagnosis.</p><p><sup>b</sup>In pairwise comparison, stages varied significantly between the moderate and advanced PD (<italic>p</italic>-value&#x02009;=&#x02009;0.0036) and between the early and advanced PD (<italic>p</italic>-value&#x02009;=&#x02009;0.0221). Stages 4 and 5 were combined into single category for Fisher&#x02019;s exact test due to low counts.</p></table-wrap-foot></table-wrap></p><p id="Par6">It is notable that &#x0003e;40% of the advanced PD group were in stage 3 or less. Given that all advanced PD participants were treated with dopaminergic medication, interpretation of staging in these medicated patients is challenging. It is certainly possible that some individuals with PD of many-years duration still have mild disease. However, two of the core assessments proposed by Dam et al. for the definition of the stages in the NSD-ISS are susceptible to medication effects: presence/absence of parkinsonism, and the Movement Disorders Society Unified Parkinsons Disease Rating Scale (MDS-UPDRS) part II (which ascertains function &#x0201c;on average&#x0201d; rather than specifically determining function in medication OFF or ON states). An examination of a selected case illustrates this point. One participant enrolled in the advanced group was a female aged 70&#x02013;74 years. Despite a disease duration of 8.3 years since diagnosis, the results of the patient and clinician-reported outcomes indicate relatively mild disease, with minimal functional impairment: Schwab and England score were 90, MDS-UPDRS part III score was 18 in the medication OFF state and 12 in the medication ON state, and Montreal Cognitive Assessment (MoCA) was 30. However, this participant was being treated with 660&#x02009;mg of levodopa equivalents, and the extent to which the functional level is a result of medication versus underlying disease severity simply cannot be ascertained.</p><p id="Par7">Four participants enrolled in the S4 PD cohort had a negative CSF asyn SAA, despite reduced DAT binding on SPECT scan. While S4 measured pathologic asyn in multiple tissues and biofluids<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>, none of the participants who had negative CSF had abnormal asyn assessed with other assays endorsed in the SynNeurGe criteria<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Thus, these individuals have parkinsonism and nigral degeneration without evidence of aggregated asyn. Whether these individuals have false negative results, have a form of pathologic asyn undetected by the methods used, or have an underlying biology that is completely independent of asyn, is unknown at this time.</p><p id="Par8">As for the NSD-ISS, results of application to a medicated cohort such as S4 emphasize the need for quantitative biomarkers of disease progression that are not influenced by medications. This will be critical before a staging system can be put forth that will be useful and widely applicable in research and the clinic without the confounds of symptomatic therapies.</p></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>A list of authors and their affiliations appears at the end of the paper.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Study participants. Ergun Uc (Medical Monitor). Jan Hamer (Biorepository). Colleen Mitchell (Biorepository). Scott Appel (Biostatistician). Dixie Ecklund (Clinical and Statistics Core). Holly Riss (Clinical and Statistics Core). Lucia Sue (Pathology Core). Anthony Intorcia (Pathology Core). Michael Glass (Pathology Core). Jessica Walker (Pathology Core). Lindsey Guilmette (Imaging Core). Vikash Oza (Dermatology Collaborator). David Lott (ENT Collaborator). Ali Keshavarzian (GI Collaborator). Julie Schneider (Pathology Collaborator). Thomas Kremer (Industry Collaborator). Christian Schmauch (Industry Collaborator). Peggy Taylor (Industry Collaborator). Trevis Huff (Clinical and Statistics Core). Danielle Smith (Biorepository). Chaucer Noyes-Lloyd (Study Coordinator). Rachael Purri (Study Coordinator). Brandon Rothberg (Study Coordinator). Courtney Blair (Study Coordinator). K. Rose case (Study Coordinator). Madeline Cresswell (Study Coordinator). Amy Duffy (Study Coordinator). Madeline Potter (Study Coordinator). General Electric for donation of DATscan<sup>TM</sup> doses in kind. This research was funded by grant ID # 025819 by the Michael J. Fox Foundation for Parkinson&#x02019;s Research (MJFF).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.M.C.: study design, data collection, drafting of manuscript. B.M.: study design, data collection, drafting of manuscript. M.C.B.: study design, data collection, data analysis, drafting of manuscript. A.R.N.: data analysis, drafting of manuscript. T.G.B.: study design, data collection, drafting of manuscript. C.H.A.: study design, data collection, drafting of manuscript. S.M.: review and revision of manuscript. N.K.P.: review and revision of manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par9">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Dam</surname><given-names>T</given-names></name><etal/></person-group><article-title>Neuronal alpha-synuclein disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts</article-title><source>NPJ Parkinsons Dis.</source><year>2024</year><volume>10</volume><fpage>178</fpage><pub-id pub-id-type="doi">10.1038/s41531-024-00789-w</pub-id><pub-id pub-id-type="pmid">39333167</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Dam, T. et al. Neuronal alpha-synuclein disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. <italic>NPJ Parkinsons Dis.</italic><bold>10</bold>, 178 (2024).<pub-id pub-id-type="pmid">39333167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Simuni</surname><given-names>T</given-names></name><etal/></person-group><article-title>A biological definition of neuronal &#x003b1;-synuclein disease: towards an integrated staging system for research</article-title><source>Lancet Neurol.</source><year>2024</year><volume>23</volume><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00405-2</pub-id><pub-id pub-id-type="pmid">38267190</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Simuni, T. et al. A biological definition of neuronal &#x003b1;-synuclein disease: towards an integrated staging system for research. <italic>Lancet Neurol.</italic><bold>23</bold>, 178&#x02013;190 (2024).<pub-id pub-id-type="pmid">38267190</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;glinger</surname><given-names>GU</given-names></name><etal/></person-group><article-title>A biological classification of Parkinson&#x02019;s disease: the SynNeurGe research diagnostic criteria</article-title><source>Lancet Neurol.</source><year>2024</year><volume>23</volume><fpage>191</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00404-0</pub-id><pub-id pub-id-type="pmid">38267191</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">H&#x000f6;glinger, G. U. et al. A biological classification of Parkinson&#x02019;s disease: the SynNeurGe research diagnostic criteria. <italic>Lancet Neurol.</italic><bold>23</bold>, 191&#x02013;204 (2024).<pub-id pub-id-type="pmid">38267191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Visanji</surname><given-names>NP</given-names></name><etal/></person-group><article-title>The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson&#x02019;s disease</article-title><source>Biomark. Med.</source><year>2017</year><volume>11</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.2217/bmm-2016-0366</pub-id><pub-id pub-id-type="pmid">28353371</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Visanji, N. P. et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson&#x02019;s disease. <italic>Biomark. Med.</italic><bold>11</bold>, 359&#x02013;368 (2017).<pub-id pub-id-type="pmid">28353371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Chahine</surname><given-names>LM</given-names></name><etal/></person-group><article-title>In vivo distribution of &#x003b1;-synuclein in multiple tissues and biofluids in Parkinson disease</article-title><source>Neurology</source><year>2020</year><volume>95</volume><fpage>e1267</fpage><lpage>e1284</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000010404</pub-id><pub-id pub-id-type="pmid">32747521</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Chahine, L. M. et al. In vivo distribution of &#x003b1;-synuclein in multiple tissues and biofluids in Parkinson disease. <italic>Neurology</italic><bold>95</bold>, e1267&#x02013;e1284 (2020).<pub-id pub-id-type="pmid">32747521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Chahine</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Central and peripheral &#x003b1;-synuclein in Parkinson disease detected by seed amplification assay</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2023</year><pub-id pub-id-type="doi">10.1002/acn3.51753</pub-id><pub-id pub-id-type="pmid">36972727</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chahine, L. M. et al. Central and peripheral &#x003b1;-synuclein in Parkinson disease detected by seed amplification assay. <italic>Ann. Clin. Transl. Neurol.</italic>10.1002/acn3.51753 (2023).<pub-id pub-id-type="pmid">36972727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Systemic Synuclein Sampling Study. <italic>Zenodo MJFF Data Repository</italic>; <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/7431680">https://zenodo.org/records/7431680</ext-link> (2022).</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Blauwendraat</surname><given-names>C</given-names></name><etal/></person-group><article-title>NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases</article-title><source>Neurobiol. Aging</source><year>2017</year><volume>57</volume><fpage>247.e249</fpage><lpage>247.e213</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.05.009</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Blauwendraat, C. et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. <italic>Neurobiol. Aging</italic><bold>57</bold>, 247.e249&#x02013;247.e213 (2017).</mixed-citation></citation-alternatives></ref></ref-list></back></article>